Spyre Therapeutics Announces Grants of Inducement Awards

Q: How many shares did Spyre Therapeutics (SYRE) grant in the January 8, 2026 inducement awards?

Spyre granted stock options to purchase an aggregate of 42,000 shares to six non-executive employees.

Q: What was the exercise price and term for the SYRE inducement stock options approved January 2, 2026?

The options have a 10-year term and an exercise price of $30.58, the closing price on January 2, 2026.

Q: What is the vesting schedule for the SYRE inducement options?

Options vest 25% on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service.

Q: Who received the SYRE inducement awards announced January 8, 2026?

The awards were granted to six non-executive employees as equity inducement awards under the 2018 Plan.

Q: Are the SYRE inducement options subject to additional plan terms or service conditions?

Yes; the options are subject to the terms of the 2018 Plan and vesting is conditioned on continuous service through applicable vesting dates.

Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan. The grants were approved on January 2, 2026 and were described as material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a 10-year term, an exercise price of $30.58 (Spyre closing price on January 2, 2026), and vest one-fourth on the first anniversary of each employee’s start date with the remainder vesting monthly at 1/48th thereafter, subject to continuous service and the terms of the 2018 Plan.

Argus Jan 9 session

+1.56% close to close Open Argus

Details

News Market Reaction – SYRE

On Jan 9, the first trading day after this news, SYRE closed 1.56% above the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Key Figures

Inducement options: 42,000 shares Grant approval date: January 2, 2026 Option term: 10 years +5 more

Inducement options: 42,000 shares; Stock options granted to six non-executive employees under 2018 Plan
Grant approval date: January 2, 2026; Date Compensation Committee approved inducement stock options
Option term: 10 years; Contractual term of inducement stock options under the 2018 Plan
Exercise price: $30.58; Equal to Nasdaq closing price of SYRE on January 2, 2026
Cliff vesting: 25% at 1 year; One-fourth of each grant vests on first employment anniversary
Ongoing vesting: 1/48th monthly; Remaining shares vest monthly thereafter, subject to service
Pre-news price: $31.05; SYRE share price before publication of inducement grant news
52-week range: $10.91–$35.31; SYRE 52-week low and high ahead of this announcement

Historical Context

5 past events · Latest: Dec 05

5 events

Dec 05
Inducement awards

24h Move

+3.5%

Stock option inducement grants totaling 20,300 options to two employees.
Nov 07
Inducement awards

24h Move

-1.5%

Inducement stock options for 19,600 shares to a new non-executive hire.
Nov 04
Earnings & update

24h Move

-0.6%

Q3 2025 results plus positive early data and 2026 Phase 2 readout plans.
Nov 04
Clinical data

24h Move

-0.6%

Positive interim Phase 1 data for SPY003 with long half-life and clean safety.
Oct 29
Investor conferences

24h Move

+1.8%

Announcement of participation in three November healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

stock options, equity inducement awards, exercise price, Nasdaq Listing Rule 5635(c)(4)

4 terms

stock options financial

"approved the grant of stock options to purchase an aggregate of 42,000 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

equity inducement awards financial

"shares of common stock of Spyre to six non-executive employees as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

exercise price financial

"a 10-year term and an exercise price equal to $30.58, the closing price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/08/2026 - 04:05 PM EST

WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,000 shares of common stock of Spyre to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on January 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $30.58, the closing price per share of Spyre's common stock as reported by Nasdaq on January 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Spyre Therapeutics (SYRE) grant in the January 8, 2026 inducement awards?

Spyre granted stock options to purchase an aggregate of 42,000 shares to six non-executive employees.

What was the exercise price and term for the SYRE inducement stock options approved January 2, 2026?

The options have a 10-year term and an exercise price of $30.58, the closing price on January 2, 2026.

What is the vesting schedule for the SYRE inducement options?

Options vest 25% on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service.

Who received the SYRE inducement awards announced January 8, 2026?

The awards were granted to six non-executive employees as equity inducement awards under the 2018 Plan.

Why did Spyre reference Nasdaq Listing Rule 5635(c)(4) for the January 2026 grants?

The company said the stock options were material to each employee's acceptance of employment and thus were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Are the SYRE inducement options subject to additional plan terms or service conditions?

Yes; the options are subject to the terms of the 2018 Plan and vesting is conditioned on continuous service through applicable vesting dates.

Spyre Therapeutics Announces Grants of Inducement Awards